Skip to main content
NewslettersWatchlist

Inmed Pharmaceuticals Inc(INM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.2620
Day High0.2924
Open:0.2700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Releases Q3 Fiscal 2024 Financial Results
Newsfile
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
Investor Brand Network
InMed (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board
Newsfile
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
Investor Brand Network
InMed (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD
Newsfile
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Releases Favorable Results from INM-901 Preclinical AD Studies
Newsfile
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Receives Notification from NASDAQ of 180-Day Extension
Newsfile
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update
Newsfile
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Names New Chief Financial Officer
Newsfile
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) CEO to Present at January Water Tower Research Fireside Chat
Newsfile
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Announces Business Update, Milestones
Newsfile
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Approves Election of Directors
Newsfile
InMed Announces Results of 2023 Annual General Meeting
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Advancing INM-089 to Target Treatment of Age-Related Macular Degeneration
Newsfile
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Announces Q1 Fiscal 2024 Financial Results
Newsfile
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) to Present Phase 2 Results for INM-755 at 12th Annual WCI
Newsfile
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
Investor Brand Network
InMed (NASDAQ: INM) Secures $5.2M in Private Placement, Preferred Investment Option Offerings
Newsfile
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) Enters Agreements for Private Placement, Preferred Investment Options
Investor Brand Network
InMed Pharmaceuticals (NASDAQ: INM) to Advance INM-901 Following Positive Proof-of-Concept Results
Newsfile
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
Newsfile
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Profile

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.